ATE337339T1 - Therapeutische verwendung von smr1 protein und seinen aktiven derivaten - Google Patents
Therapeutische verwendung von smr1 protein und seinen aktiven derivatenInfo
- Publication number
- ATE337339T1 ATE337339T1 AT98912339T AT98912339T ATE337339T1 AT E337339 T1 ATE337339 T1 AT E337339T1 AT 98912339 T AT98912339 T AT 98912339T AT 98912339 T AT98912339 T AT 98912339T AT E337339 T1 ATE337339 T1 AT E337339T1
- Authority
- AT
- Austria
- Prior art keywords
- therapeutic
- well
- molecules
- present
- preventing
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 5
- 101100533725 Mus musculus Smr3a gene Proteins 0.000 title 1
- 101100149716 Rattus norvegicus Vcsa1 gene Proteins 0.000 title 1
- 101150037481 SMR1 gene Proteins 0.000 title 1
- 101100286750 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ILV2 gene Proteins 0.000 title 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 239000011707 mineral Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108090000244 Rat Proteins Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 210000003298 dental enamel Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000001156 gastric mucosa Anatomy 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000000762 glandular Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/854—Glands
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/801,405 US6589750B2 (en) | 1997-02-20 | 1997-02-20 | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE337339T1 true ATE337339T1 (de) | 2006-09-15 |
Family
ID=25181003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98912339T ATE337339T1 (de) | 1997-02-20 | 1998-02-19 | Therapeutische verwendung von smr1 protein und seinen aktiven derivaten |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US6589750B2 (de) |
| EP (2) | EP1702929A3 (de) |
| AT (1) | ATE337339T1 (de) |
| AU (1) | AU6721998A (de) |
| CA (1) | CA2281912A1 (de) |
| DE (1) | DE69835680T2 (de) |
| DK (1) | DK1007566T3 (de) |
| ES (1) | ES2271991T3 (de) |
| PT (1) | PT1007566E (de) |
| WO (1) | WO1998037100A2 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
| WO2001000221A2 (en) * | 1999-06-23 | 2001-01-04 | Institut Pasteur | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| EP1216707B1 (de) | 2000-12-22 | 2005-02-09 | Institut Pasteur | Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| DE602004028678D1 (de) | 2003-01-28 | 2010-09-23 | Ironwood Pharmaceuticals Inc | Zusammensetzungen zur Behandlung von Magen-Darm-Störungen |
| DK1577320T3 (da) * | 2004-03-19 | 2012-10-15 | Pasteur Institut | Peptider afledt fra humant BPLP-protein, polynukleotider kodende for nævnte peptider og antistoffer rettet mod nævnte peptider |
| DE102004026744A1 (de) * | 2004-05-28 | 2005-12-29 | Philipps-Universität Marburg | Erfindung betreffend cDNA-Herstellung aus Zellen nach Laser-Mikrodissektion |
| US8034782B2 (en) | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| RU2542365C2 (ru) | 2008-04-07 | 2015-02-20 | Энститю Пастёр | Производные опиорфинного пептида как потенциальные ингибиторы эктопептидаз, участвующих в деградации энкефалинов |
| FR2931362B1 (fr) * | 2008-05-26 | 2017-08-18 | Pasteur Institut | L'opiorphine pour une utilisation en tant que psychostimulant. |
| EP2810951B1 (de) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase |
| AU2009322285B2 (en) | 2008-12-03 | 2016-07-28 | Bausch Health Ireland Limited | Formulations of guanylate cyclase C agonists and methods of use |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CN107090016A (zh) | 2011-03-01 | 2017-08-25 | 辛纳吉制药公司 | 制备鸟苷酸环化酶c激动剂的方法 |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
| CN109212006A (zh) * | 2018-08-24 | 2019-01-15 | 北京艾普希隆生物科技有限公司 | 一种单细胞琼脂糖凝胶电泳试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1983003972A1 (en) | 1982-05-06 | 1983-11-24 | Massachusetts Institute Of Technology | Production of enterovirus neutralizing antibodies from vp1 |
| US4699877A (en) | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
| GB8327966D0 (en) | 1983-10-19 | 1983-11-23 | Nyegaard & Co As | Chemical compounds |
| IL78444A (en) * | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
| FR2637600B1 (fr) * | 1988-10-11 | 1992-03-06 | Pasteur Institut | Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques |
| US5219548A (en) * | 1990-10-01 | 1993-06-15 | Board Of Regents, The University Of Texas System | High affinity halogenated-tamoxifen derivatives and uses thereof |
| WO1995000848A1 (en) * | 1993-06-23 | 1995-01-05 | The Regents Of The University Of California | Compositions and methods for anti-addictive narcotic analgesis acivity screening and treatments |
| US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
| WO2001000221A2 (en) * | 1999-06-23 | 2001-01-04 | Institut Pasteur | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| EP1216707B1 (de) * | 2000-12-22 | 2005-02-09 | Institut Pasteur | Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden |
-
1997
- 1997-02-20 US US08/801,405 patent/US6589750B2/en not_active Expired - Lifetime
-
1998
- 1998-02-19 CA CA002281912A patent/CA2281912A1/en not_active Abandoned
- 1998-02-19 EP EP06009596A patent/EP1702929A3/de not_active Withdrawn
- 1998-02-19 PT PT98912339T patent/PT1007566E/pt unknown
- 1998-02-19 ES ES98912339T patent/ES2271991T3/es not_active Expired - Lifetime
- 1998-02-19 AT AT98912339T patent/ATE337339T1/de active
- 1998-02-19 EP EP98912339A patent/EP1007566B1/de not_active Expired - Lifetime
- 1998-02-19 WO PCT/EP1998/000956 patent/WO1998037100A2/en not_active Ceased
- 1998-02-19 DK DK98912339T patent/DK1007566T3/da active
- 1998-02-19 DE DE69835680T patent/DE69835680T2/de not_active Expired - Lifetime
- 1998-02-19 AU AU67219/98A patent/AU6721998A/en not_active Abandoned
- 1998-02-19 US US09/367,703 patent/US6818405B2/en not_active Expired - Fee Related
-
2003
- 2003-05-12 US US10/435,564 patent/US20030195155A1/en not_active Abandoned
- 2003-07-17 US US10/620,462 patent/US7429448B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1702929A2 (de) | 2006-09-20 |
| DE69835680T2 (de) | 2007-08-23 |
| US6818405B2 (en) | 2004-11-16 |
| ES2271991T3 (es) | 2007-04-16 |
| WO1998037100A2 (en) | 1998-08-27 |
| US20040047805A1 (en) | 2004-03-11 |
| US20030195155A1 (en) | 2003-10-16 |
| US20020019008A1 (en) | 2002-02-14 |
| AU6721998A (en) | 1998-09-09 |
| PT1007566E (pt) | 2007-01-31 |
| US20020198361A1 (en) | 2002-12-26 |
| DK1007566T3 (da) | 2007-01-02 |
| WO1998037100A3 (en) | 1999-01-07 |
| EP1007566A2 (de) | 2000-06-14 |
| US7429448B2 (en) | 2008-09-30 |
| US6589750B2 (en) | 2003-07-08 |
| CA2281912A1 (en) | 1998-08-27 |
| EP1007566B1 (de) | 2006-08-23 |
| DE69835680D1 (de) | 2006-10-05 |
| EP1702929A3 (de) | 2007-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE337339T1 (de) | Therapeutische verwendung von smr1 protein und seinen aktiven derivaten | |
| EA200200755A1 (ru) | Опосредованная рецептором nogo блокада роста аксонов | |
| NO953781L (no) | Terapeutisk anvendelse av keratinocyttvekstfaktor | |
| AU1922101A (en) | Human fgf-21 gene and gene expression products | |
| ATE467425T1 (de) | Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben | |
| EA200300845A1 (ru) | Модифицированные антитела и способы применения | |
| RU94045281A (ru) | Иммуноконъюгаты, способ получения иммуноконъюгата, фармацевтическая композиция, применение иммуноконъюгата | |
| ATE342358T1 (de) | Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen | |
| DE60128916D1 (de) | Neues, physiologisch aktives peptid und dessen verwendung | |
| DE69840909D1 (de) | Analoge von kokain | |
| PL2157192T3 (pl) | Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin) | |
| NZ279963A (en) | Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946 | |
| DE69727691D1 (de) | Verwendung von keratinocyten-wachstumsfaktor-2 | |
| DK1165102T3 (da) | Matrixproteinpræparater til podning i ikke-mineraliseret væv | |
| KR100488038B1 (ko) | 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도 | |
| WO2002007676A3 (en) | Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr) | |
| DE69712182D1 (de) | Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises | |
| RU94039629A (ru) | Стимулятор роста костномозговых клеток человека | |
| WO2000026362A3 (de) | Proteine der stomatinfamilie und ihre verwendung als zielproteine für die schmerztherapie | |
| AU7435298A (en) | Compositions for enhancing immunosuppressants' pharmaceutical acti vities | |
| UA28342A (uk) | Спосіб одержання біологічно активної речовини для лікування серцевих захворювань |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1007566 Country of ref document: EP |